Pfizer Global Medical Grants – Request for Proposals (RFP) Interventional Research Studies with Elranatamab

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date RFP Issued: June 7, 2024
Geographic Scope: Global
Clinical Area: Oncology – Hematology – Multiple Myeloma
Application Due Date: July 18, 2024
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on generating evidence on priority gaps in the use of elranatamab in multiple myeloma across lines of treatment, and in particular:

• Combination with novel agents
• Frontline use of elranatamab in newly diagnosed multiple myeloma, including sequencing with autologous Stem-Cell Transplant (ASCT)/Chimeric Antigen Receptor T-cells (CAR-T), focus on subpopulations of unmet needs, segmentation based on disease biology
• Optimal administration of elranatamab treatment in patient subpopulations based on patients (e.g. age/fitness/comorbidities), risk (e.g. HRCA, extramedullary disease, high tumor burden) and response characteristics
• Characterization, monitoring, and mitigation strategies of: Infections, CRS, Neurotoxicity/ ICANS, viral reactivation (incl. observing and monitoring emerging infections), other adverse events of elranatamab treatment
• Investigation and intervention of resistance/relapse mechanisms to elranatamab treatment, with focus on strategies to mitigate T-cell exhaustion and its clinical outcomes
• Retreatment-rechallenging strategies

If you have questions regarding this RFP, please direct them in writing to Jacqueline Waldrop, Grant Officer ([email protected]).

PP-E1A-GBR-0227
June 2024

 

Latest News

By BOPA Committee on 22nd July 2024

REMINDER – 2024 Elections to the BOPA Executive Committee: Call for nomination of members

BOPA is looking for new Executive Committee members who are dedicated to furthering the association’s aims and who are willing, and able, to spend time helping run the organisation. Those…

Read article
By BOPA Committee on 12th July 2024

TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients

BOPA is delighted to announce the publication of TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients in collaboration with OUTpatients. It is estimated that one…

Read article
By BOPA Committee on 11th July 2024

Round Table Discussion at #BOPA2024

  As an exciting addition to the 2024 conference, we invite you all to participate in one of our interactive sessions on the Sunday morning. We have a lineup of…

Read article
By BOPA Committee on 10th July 2024

APTUK Position Statement for DHSC PGD Update

The Association of Pharmacy Technicians UK (APTUK), as the professional leadership body for pharmacy technicians, welcome the positive outcome of the DHSC consultation supporting the enabling of registered pharmacy technicians…

Read article